Cargando…

Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?

BACKGROUND: Literature explains participation limitations among people with schizophrenia through the context of metacognitive limitations, specifically in symptoms and in executive functions (EF). Research has shown mixed results regarding associations between symptoms and participation, reporting...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaizerman-Dinerman, Alona, Roe, David, Demeter, Naor, Josman, Naomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844002/
https://www.ncbi.nlm.nih.gov/pubmed/36650458
http://dx.doi.org/10.1186/s12888-022-04510-0
_version_ 1784870525027221504
author Kaizerman-Dinerman, Alona
Roe, David
Demeter, Naor
Josman, Naomi
author_facet Kaizerman-Dinerman, Alona
Roe, David
Demeter, Naor
Josman, Naomi
author_sort Kaizerman-Dinerman, Alona
collection PubMed
description BACKGROUND: Literature explains participation limitations among people with schizophrenia through the context of metacognitive limitations, specifically in symptoms and in executive functions (EF). Research has shown mixed results regarding associations between symptoms and participation, reporting association with negative symptoms, positive symptoms, or only metacognitive limitations. The aim of this study was to deepen understanding of the symptoms’ impact on the association between participation and executive function among people with schizophrenia. METHODS: Forty-three participants with schizophrenia received 8 group sessions of focused metacognitive intervention (MCG) aimed at promoting participation by focusing on EF components (e.g., analyzing individual cognitive strategy use). Three measures were administered: the Positive and Negative Syndrome Scale (PANSS) to evaluate symptoms, the Weekly Calendar Planning Assessment (WCPA) to assess EF, and the Activity Card Sort (ACS) to measure participation at the baseline and 12 weeks following completion of the intervention. Scores were compared to a matched control group of 41 people with schizophrenia who instead received treatment as usual. The role of PANSS as moderator was examined using multiple hierarchical regressions, entering interactions between the PANSS scores and WCPA change scores in the final regression step. RESULTS: Relationships were not significant for participants with high PANSS scores. A positive relationship existed between change in WCPA and change in ACS for participants with low PANSS scores. CONCLUSIONS: These results demonstrate that low PANSS scores moderate the association between EF and participation and highlight the importance of symptoms as a predictor of participation following the MCG intervention. TRIAL REGISTRATION: The trial was retrospectively registered at clinical.trial.gov. ClinicalTrials.gov Identifier: NCT05556941. Clinicaltrial.gov registration date: 27/09/2022.
format Online
Article
Text
id pubmed-9844002
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98440022023-01-18 Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia? Kaizerman-Dinerman, Alona Roe, David Demeter, Naor Josman, Naomi BMC Psychiatry Research BACKGROUND: Literature explains participation limitations among people with schizophrenia through the context of metacognitive limitations, specifically in symptoms and in executive functions (EF). Research has shown mixed results regarding associations between symptoms and participation, reporting association with negative symptoms, positive symptoms, or only metacognitive limitations. The aim of this study was to deepen understanding of the symptoms’ impact on the association between participation and executive function among people with schizophrenia. METHODS: Forty-three participants with schizophrenia received 8 group sessions of focused metacognitive intervention (MCG) aimed at promoting participation by focusing on EF components (e.g., analyzing individual cognitive strategy use). Three measures were administered: the Positive and Negative Syndrome Scale (PANSS) to evaluate symptoms, the Weekly Calendar Planning Assessment (WCPA) to assess EF, and the Activity Card Sort (ACS) to measure participation at the baseline and 12 weeks following completion of the intervention. Scores were compared to a matched control group of 41 people with schizophrenia who instead received treatment as usual. The role of PANSS as moderator was examined using multiple hierarchical regressions, entering interactions between the PANSS scores and WCPA change scores in the final regression step. RESULTS: Relationships were not significant for participants with high PANSS scores. A positive relationship existed between change in WCPA and change in ACS for participants with low PANSS scores. CONCLUSIONS: These results demonstrate that low PANSS scores moderate the association between EF and participation and highlight the importance of symptoms as a predictor of participation following the MCG intervention. TRIAL REGISTRATION: The trial was retrospectively registered at clinical.trial.gov. ClinicalTrials.gov Identifier: NCT05556941. Clinicaltrial.gov registration date: 27/09/2022. BioMed Central 2023-01-17 /pmc/articles/PMC9844002/ /pubmed/36650458 http://dx.doi.org/10.1186/s12888-022-04510-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kaizerman-Dinerman, Alona
Roe, David
Demeter, Naor
Josman, Naomi
Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?
title Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?
title_full Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?
title_fullStr Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?
title_full_unstemmed Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?
title_short Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?
title_sort do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844002/
https://www.ncbi.nlm.nih.gov/pubmed/36650458
http://dx.doi.org/10.1186/s12888-022-04510-0
work_keys_str_mv AT kaizermandinermanalona dosymptomsmoderatetheassociationbetweenparticipationandexecutivefunctionsoutcomesamongpeoplewithschizophrenia
AT roedavid dosymptomsmoderatetheassociationbetweenparticipationandexecutivefunctionsoutcomesamongpeoplewithschizophrenia
AT demeternaor dosymptomsmoderatetheassociationbetweenparticipationandexecutivefunctionsoutcomesamongpeoplewithschizophrenia
AT josmannaomi dosymptomsmoderatetheassociationbetweenparticipationandexecutivefunctionsoutcomesamongpeoplewithschizophrenia